A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509573-23-00

Acronym

AB-729-203

Enrollment

Registered

2024-06-10

Start date

2024-07-16

Completion date

2024-08-01

Last updated

2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic HBV Infection

Brief summary

The frequency and severity of treatment emergent adverse events (TEAEs) and irAEs, and discontinuations due to AEs and irAEs, The frequency and severity of laboratory abnormalities by cohort, Vital signs, physical exam and electrocardiogram (ECG) abnormalities

Interventions

DRUGImdusiran

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The frequency and severity of treatment emergent adverse events (TEAEs) and irAEs, and discontinuations due to AEs and irAEs, The frequency and severity of laboratory abnormalities by cohort, Vital signs, physical exam and electrocardiogram (ECG) abnormalities	—

Countries

France, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026